New approaches to measuring anthelminthic drug efficacy : parasitological responses of childhood schistosome infections to treatment with praziquantel by Walker, Martin et al.
RESEARCH Open Access
New approaches to measuring
anthelminthic drug efficacy: parasitological
responses of childhood schistosome
infections to treatment with praziquantel
Martin Walker1,2*†, Tarub S. Mabud1,16†, Piero L. Olliaro3,4, Jean T. Coulibaly5,6,7,8, Charles H. King9,10,
Giovanna Raso5,6, Alexandra U. Scherrer11, J. Russell Stothard12, José Carlos Sousa-Figueiredo13,14, Katarina Stete15,
Jürg Utzinger5,6 and Maria-Gloria Basáñez1,2
Abstract
Background: By 2020, the global health community aims to control and eliminate human helminthiases, including
schistosomiasis in selected African countries, principally by preventive chemotherapy (PCT) through mass drug
administration (MDA) of anthelminthics. Quantitative monitoring of anthelminthic responses is crucial for promptly
detecting changes in efficacy, potentially indicative of emerging drug resistance. Statistical models offer a powerful
means to delineate and compare efficacy among individuals, among groups of individuals and among populations.
Methods: We illustrate a variety of statistical frameworks that offer different levels of inference by analysing data from
nine previous studies on egg counts collected from African children before and after administration of praziquantel.
Results: We quantify responses to praziquantel as egg reduction rates (ERRs), using different frameworks to estimate
ERRs among population strata, as average responses, and within strata, as individual responses. We compare our model-
based average ERRs to corresponding model-free estimates, using as reference the World Health Organization (WHO)
90 % threshold of optimal efficacy. We estimate distributions of individual responses and summarize the variation
among these responses as the fraction of ERRs falling below the WHO threshold.
Conclusions: Generic models for evaluating responses to anthelminthics deepen our understanding of variation among
populations, sub-populations and individuals. We discuss the future application of statistical modelling approaches for
monitoring and evaluation of PCT programmes targeting human helminthiases in the context of the WHO 2020 control
and elimination goals.
Keywords: Schistosomiasis, Praziquantel, Anthelminthic drug efficacy, Egg reduction rate, Conditional models, Marginal
models, Bayesian methods
* Correspondence: m.walker06@imperial.ac.uk
†Equal contributors
1Department of Infectious Disease Epidemiology, School of Public Health,
Faculty of Medicine (St Mary’s Campus), Imperial College London, London
W2 1PG, UK
2London Centre for Neglected Tropical Disease Research, Department of
Infectious Disease Epidemiology, Imperial College London, London W2 1PG,
UK
Full list of author information is available at the end of the article
© 2016 Walker et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Walker et al. Parasites & Vectors  (2016) 9:41 
DOI 10.1186/s13071-016-1312-0
Background
Human helminthiases comprise six of the seven most
prevalent neglected tropical diseases (NTDs) [1] that are
targeted by the World Health Organization (WHO) for
elimination, where feasible, by 2020 [2]. Schistosomiasis
infects over 250 million people with an estimated global
burden of 3.31 million disability-adjusted life years [3, 4].
The main strategy to control and eliminate human hel-
minthiases is preventative chemotherapy (PCT) by mass
drug administration (MDA) using a handful of safe and ef-
ficacious anthelminthic drugs [5–7]. The cornerstone of
schistosomiasis control and elimination efforts is prazi-
quantel which is effective in killing adult Schistosoma
mansoni, S. haematobium and S. japonicum, the most glo-
bally important causes of intestinal, urogenital and Asian
intestinal schistosomiasis, respectively.
The reliance on single drugs with essentially no avail-
able alternatives makes the long-term effectiveness of
the PCT strategy susceptible to the potentially devastat-
ing consequences of emerging anthelminthic resistance.
Although examples of praziquantel-resistant isolates of
S. mansoni are currently scant and virtually non-existent
for S. haematobium or S. japonicum [8], there is broad con-
sensus that the efficacy of praziquantel—and other anthel-
minthics used for MDA—should be monitored to detect
atypical responses that may indicate dwindling efficacy,
possibly caused by emerging drug resistance [6, 9–12].
The efficacy of anthelminthics is typically expressed as
either a cure rate (CR), or an intensity reduction rate (IRR;
Table 1), calculated using data on parasite transmission
stages collected before and after treatment. Intensity reduc-
tion rates are recommended by the WHO for monitoring
the efficacy of both praziquantel and the benzimidazoles,
which are widely used in PCT targeting soil-transmitted
helminthiasis [13]. In this context, IRRs are calculated
using data on helminth egg counts and so are referred to
as egg reduction rates (ERRs). The methods of estimating
ERRs can be divided into model-free and model-based
approaches.
Model-free approaches calculate ERRs directly from
data using simple arithmetic operations, without invoca-
tion of distributional (modelling) assumptions. These so-
called sample estimates are easy to calculate and
straightforward to interpret as population averages [14]
and are the most commonly reported estimates of effi-
cacy [15, 16]. Although egg count values are not nor-
mally distributed even after log transformation, the
WHO recommends arithmetic means over geometric
means [13] as the former are more sensitive to outliers
and thus more apt to identify suboptimal group re-
sponses [14]. However, they are not readily compatible
with exploring associations between efficacy and covari-
ates, nor do they permit inference on the underlying dis-
tribution of drug responses among individuals.
Model-based approaches are seldom used to estimate
efficacy, despite offering a powerful means to conduct
multivariate analyses of longitudinal data [17] on egg
counts to delineate and compare efficacy among individ-
uals, among groups of individuals and among popula-
tions. Furthermore, modelling approaches, particularly
in conjunction with Bayesian techniques, can be used to
define distributions of responses to anthelminthics
among individuals within demographic strata and among
populations [16].
Here, we illustrate two distinct modelling approaches by
analysing data on schistosome egg counts collected from
children infected with S. mansoni or S. haematobium be-
fore and up to six weeks after administration of prazi-
quantel. The data are from several past studies on the
efficacy of praziquantel from communities in Côte
d’Ivoire, Kenya and Uganda, predominantly naïve to
MDA, or having received only a few rounds of MDA. We
illustrate how two classes of statistical model can be used
to (i) identify geographical, demographic and drug regi-
men covariates associated with ERRs and (ii) explore dis-
tributions of individual responses to praziquantel in key
population demographics and evaluate the frequency of
nominally optimal and sub-optimal responders. We dis-
cuss the context in which each modelling approach is
most appropriate, depending on the goal of the analysis
and the level of inference sought [18]. We also describe
how distributions of drug responses among individuals
infected with predominantly drug-naïve and maximally
susceptible parasites could facilitate identification of sub-
optimally or atypically responding individuals, ultimately
providing a practical tool for the monitoring and evalu-
ation (M&E) of anthelmintic efficacy during PCT
programmes.
Models and methods
Ethics, consent and permissions
This paper reports a secondary analysis of data collected in
past studies, all of which obtained the necessary ethical
approvals from relevant institutional review boards and local
and national ethics committees. All data were collected in
accordance with international ethical standards. Data re-
ceived were completely and irreversibly anonymised. Add-
itional information can be found in the original publications
and in Additional file 1: Supplementary Tables, Table S1.
Data selection criteria
We obtained the datasets presented in Olliaro et al. [14] that
comprise individual-level data on schistosome egg counts
measured before and after administration of praziquantel,
collected from 13 studies (Additional file 1: Supplementary
Tables, Table S1). The data also comprise individual covari-
ates including: age; sex; dose of praziquantel, and days of
follow-up after treatment, and the population covariate,
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country. Studies were largely non-controlled, non-blinded
public health interventions, with one exception [19], which
was placebo-controlled and double blinded. Placebo-
controlled randomised controlled trials have been rare for
helminthiases as it is now generally considered unethical to
withhold effective treatment from infected individuals.
Following the criteria outlined in Fig. 1, we selected three
studies with data on S. haematobium [19–21], and six
studies with data on S. mansoni [19, 22–26] infections in
children. Key features of these datasets are summarised in
Table 1 Definitions
Term Definition
Bayesian credible interval (BCI) An interval of a posterior distribution that defines the domain within which the value of a parameter
lies with a specified probability (typically 0.95 or 95 %). The Bayesian analogy to the classical frequentist
confidence interval.
Best linear unbiased prediction (BLUP) A frequentist technique used in linear mixed models to estimate random effects terms, so-called
empirical best linear unbiased predictors (EBLUPs).
Bootstrapping A numerical resampling technique typically used to generate estimates of uncertainty associated with
calculated statistical quantities.
Cure rate (CR) Proportion of individual hosts positive for parasites who become parasitologically negative after
treatment.
Intensity reduction rate (IRR)/egg reduction
rate (ERR)
The intensity of infection after treatment expressed as a proportion of the intensity of infection before
treatment. For schistosomiasis (and soil-transmitted helminthiases), this is typically expressed as an egg
reduction rate; the egg count after treatment expressed as a proportion of the egg count before treatment.
Drug response Dynamics of parasite (transmission) stages following anthelminthic treatment.
Fixed effect The component of an effect exerted by a particular value or level of a covariate that is the same
among all observations within a unit of a structured dataset
Generalized estimating equation (GEE) A technique for estimating the parameters of a marginal model fitted to correlated repeated
measures (observations). The GEE approach is semi-parametric because it relies on the first two
moments of the observed data, but not on the full likelihood.
Generalized linear model (GLM) An extension of the simple linear regression model that is compatible with error distributions
from any of the exponential family of probability distributions, including the normal, Poisson,
binomial, and gamma distributions. The simple linear regression model is a GLM with normally
distributed errors.
Conditional (linear) mixed model (also called
a generalized linear mixed model, GLMM)
An extended GLM that includes a linear predictor comprised of covariate coefficients that exert
both fixed and random effects.
Hyperparameter A parameter in a hieracrchical or multilevel statistical model that governs the distribution of
lower-level random effects terms
Marginal model An adaptation of a GLM for use with correlated repeated measures (observations). Marginal
refers to the marginal mean of observations from individuals (units) sharing a set of covariates.
A marginal model comprises three model components; a marginal mean, which depends on
covariates; a marginal variance, which is typically a function of the marginal mean, and a
correlation structure for the repeated measures.
Markov chain Monte Carlo (MCMC) A stochastic algorithm central to Bayesian statistical inference which samples parameter values
from the posterior probability distribution by combining information from the likelihood of the
observed data and the prior probability distribution of the parameters.
Random effects The component of an effect exerted by a particular value or level of a covariate that is different
among observations within a unit of a structured dataset. The magnitude of the deviations from
the fixed effect component is governed by (typically a normal) distribution defined by estimable
hyperparameters.
Repeated measures Measurements or observations made repeatedly on the same unit, for example, multiple
schistosome egg counts measured from the same individual host.
Restricted maximum likelihood (REML)
estimation
An alternative to maximum likelihood (ML) estimation for models that include random effects. In
REML estimation, the dispersion of the random effects is estimated having averaged over some of
the uncertainty in the fixed effects. By contrast, in ML estimation, the fixed effects estimates are
treated as precisely correct.
Sandwich estimator A standard error (SE) of an estimated quantity that is robust to misspecifications in the
variance-covariance of the error distribution in a statistical model. Sandwich estimators are typically
used with marginal models so that SEs (and confidence intervals) are invariant to inaccuracies
in the specification of the repeated measures correlation structure. In this context, sandwich
estimators are based on the empirically observed variation among unit-level statistics rather than
on the model-derived variance-covariance matrix which depends on the assumed correlation structure.
Definitions are taken from Walker et al. [16]
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Table 2 with further details given in Additional file 1:
Supplementary Tables, Table S1. Raw egg counts and
child-specific mean egg counts before and after treatment
with praziquantel are depicted in Fig. 2.
Model-free approach
We calculated model-free sample ERRs [13] using
Sample ERR ¼ 1 ‐ mean egg count after treatment
mean egg count before treatment
;
ð1Þ
which we compared with model-based estimates. We used
a non-parametric percentile block bootstrap method
(Table 1) to calculate associated 95 % confidence intervals
(CIs). Block bootstrap methods [27] account for correl-
ation among observations (egg counts) from the same in-
dividual by randomly sampling (with replacement) blocks
of data; in this case, all of an individual’s egg counts before
and after treatment. Details are given in Additional file 1:
Supplementary Methods S1 Percentile block bootstrap.
Modelling approach
We employed marginal models and conditional mixed
models [17] to estimate ERRs [16]. These are two dis-
tinct classes of statistical regression model suitable for
analysing dependent (clustered/correlated) data, which
here arises because egg counts are measured repeatedly
from the same individual and individuals are sampled re-
peatedly within the same study. We defined two variants
6 studies including 
data on Schistosoma 
haematobium 
(n = 2,300) 
Selection criteria 
Study communities not previously been involved in mass drug administration (MDA) 
programmes
School-aged children <18 years 
Schistosoma haematobium or S. mansoni infection diagnosed by urine filtration or Kato-
Katz technique, respectively 
Egg counts measured before and after treatment with a single dose of praziquantel only 
No enrollment criteria based on egg counts measured before treatment 
Children followed up < 6 weeks after treatment 
Recorded individual-level characteristics, including age, sex, country etc. 
8 studies including 
data on Schistosoma 
mansoni 
(n = 2,311) 
3 studies included
(n = 171) 
3 studies excluded 
due to: 
missing raw egg 
counts 
multi-dose drug 
regimens 
follow-up times >6 
weeks 
6 studies included
(n = 991) 
2 studies excluded 
due to: 
missing raw egg 
counts 
multi-dose drug 
regimens 
enrollment 
conditional on egg 
counts  
Fig. 1 Data selection criteria
Table 2 Summary of data included in the analysis
Country Participants Mean age (SD) QD protocola PZQ regimen Follow-up days Ref.
Schistosoma haematobium
Côte d’Ivoire 6 5 (0) 1 UF × 1 urine sample 1 × 40 mg/kg 21 [20]
Côte d’Ivoire 86 11.1 (1.9) 1 UF × 2 urine samples 1 × 40 mg/kg 21 [21]
Kenya 79 11.3 (3.1) 1 UF × 4 urine samples 1 × 40 mg/kg 42 [19]
Schistosoma mansoni
Côte d’Ivoire 35 3.8 (1.2) 2 KK × 2 stool samples 1 × 40 mg/kg 21 [20]
Uganda 503 4.2 (1.8) 2 KK × 2 stool samples 1 × 40 mg/kg 21 [26]
Côte d’Ivoire 58 11.2 (4.1) 1 KK × 3 stool samples 1 × 40 mg/kg 42 [24]
Côte d’Ivoire 49 8.9 (2.4) 2 KK × 2 stool samples 1 × 40 mg/kg 21 [25]
Côte d’Ivoire 85 10.0 (1.42) 1 KK x 4 stool samples 1 × 40 mg/kg 28 [23]
Côte d’Ivoire 261 9.6 (2.1) 1 KK x 5 stool samples 1 × 60 mg/kgb 28 [22]
Abbreviations: KK Kato-Katz, PZQ praziquantel, QD quantitative diagnostic, SD standard deviation, UF urine filtration
aMultiple samples of urine or stool were taken on consecutive days; b 2 × 30 mg/kg given 3 hours apart
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of the latter, one in a classical (frequentist) manner, and
the other in a Bayesian framework. Full mathematical
details of the models are given in the Additional file 1:
Supplementary Methods sections S2 Marginal models,
S3 Conditional mixed models, and S4 Bayesian condi-
tional mixed models. Here, we give a brief synopsis of
the model classes and a description of the salient fea-
tures for estimating ERRs. Key distinctions are sum-
marised in Table 3.
Marginal models offer population average (marginal)
inference, empirically accounting for the dependence of
the data using a postulated correlation matrix. In com-
bination with sandwich estimators (Table 1) of coeffi-
cient standard errors, marginal models yield robust
estimates of uncertainty. Conditional mixed models offer
inference at the level of the individual by modelling ex-
plicitly the conditional dependence of the data using
fixed and random effects. This permits estimation of in-
dividual ERRs and the degree of variation among them.
By casting conditional mixed models in a Bayesian archi-
tecture— defining the necessary parameter prior distri-
butions—one can fully integrate uncertainty into the
estimated posteriors and hence derive robust indices of
uncertainty, including those associated with the esti-
mated distribution of ERRs among individuals.
The essential ingredient of both model classes (mar-
ginal and conditional mixed models) is a log-linear re-
gression structure that describes the change in egg
counts after treatment, x = 1, compared to before treat-
ment, x = 0, in a multiplicative fashion. Hence, the ac-
companying regression coefficient β quantifies the risk
ratio (RR) of egg counts after treatment compared to be-
fore treatment, and the ERR is given (generically) by 1 –
exp(βx). Covariates enter the regression structure as
interacting with x. In marginal models this permits ERRs
to vary among strata. In conditional mixed models, this
permits ERRs to vary also among strata, via fixed effects,
and additionally among individuals, via random effects.
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Fig. 2 Schistosome egg counts by number of days after treatment with praziquantel. Panel a depicts Schistosoma haematobium egg counts
measured by urine filtration. Panel b depicts S. mansoni egg counts measured by Kato-Katz technique. Each data point represents a single count
(i.e. not an average of multiple counts). Panels c and d depict the arithmetic mean egg counts per person connected by a line. Treatment with
praziquantel occurred following the counts made at day zero
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Inference
We defined marginal and conditional mixed models
separately for the S. haematobium and S. mansoni data-
sets, including the covariates of ERRs listed in Table 4.
In the conditional mixed models, these covariates were
treated as exerting both fixed and random effects per-
mitting variation among population strata and among in-
dividuals within strata. We fitted the models in R [28]
using: (a) generalized estimating equation techniques, im-
plemented with the geepack package (marginal models)
[29]; (b) restricted maximum likelihood estimation by
Laplace approximation, implemented with lme4 (condi-
tional mixed models) [30]; and (c) Markov chain Monte
Carlo (MCMC) methods, implemented with MCMCglmm
(Bayesian conditional mixed models) [31] (see Table 1 for
descriptions of these statistical techniques). We ran three
MCMC chains for the Bayesian models, monitoring for
convergence and checking that our final conclusions were
not dependent on the choice of initial values [32]. In
general, 5,000 iterations were discarded as burn-in and an
additional 20,000 were sufficient to estimate parameter
posterior distributions.
Results
Average egg reduction rates
The model-free sample estimates of S. haematobium
and S. mansoni average ERRs following treatment with
praziquantel, aggregated across studies, are—with 95 %
CIs given in parentheses—99.3 % (98.7 %, 99.7 %) and
83.8 % (77.7 %, 88.9 %), respectively. The corresponding
marginal-model estimates (excluding covariates) are
99.6 % (98.1 %, 99.9 %) and 77.9 % (72.7 %, 82.0 %),
respectively. The notable difference between the model-
free and model-based estimates for S. mansoni is be-
cause the marginal model accounts for the correlation
among the repeated measures. This is compounded by
the high variation among the number of observations
per individual, which ranged from 4 to 37 [22].
Stratum average egg reduction rates
The average ERRs and their accompanying CIs estimated
for each stratum (defined by the covariates listed in
Table 4) using the model-free and marginal model ap-
proaches are depicted in Fig. 3. The two approaches
yield similar estimates, albeit the assumptions of the
modelling approach stabilise estimates in some poorly
populated strata, and generally reduce variation. More-
over, model-free bootstrap CIs cannot be constructed in
some strata because no eggs were counted in any sam-
ples after treatment. Therefore, in these strata, the esti-
mated ERRs are 100 % with no associated uncertainty
(grey circles, Fig. 3b). Some of the model-based average
ERRs among children infected with S. mansoni fall
below the WHO’s 90 % threshold of ‘optimal’ praziquan-
tel efficacy albeit less so at 21 days, which is the WHO-
recommended maximum follow-up time (Fig. 3b) [13].
Underlying the marginal-model estimates shown in
Fig. 3 are the estimated covariate coefficients. These are
presented in the form of RRs in Fig. 4, alongside accom-
panying 95 % CIs. We also present the ERRs
Table 3 Summary of approaches used to estimate egg reduction rates among children infected with schistosomes following
treatment with praziquatel
Approach Method Required parametric assumptions Inference
Model-free Sample statistics • None • Population average estimates
Model-based Marginal models • Variance to mean relationship
• Correlation structure among repeated measures
• Population average estimates
• Covariate effects
Conditional mixed models • Conditional distribution of data
• Distribution of random effects
• Individual estimates
• Covariate effects
Bayesian conditional mixed models • Conditional distribution of data
• Distribution of random effects
• Prior distribution of parameters
• Individual estimates
• Covariate effects
• Fully integrated parameter uncertainty
Table 4 Covariates included in the regression models used to
estimate egg reduction rates among children infected with
schistosomes following treatment with praziquatel
Covariate Levels
Schistosoma haematobium
dataset
Schistosoma mansoni
dataset
Country Côte d’Ivoire Côte d’Ivoire
Kenyaa Uganda
Dose 40 mg/kg 40 mg/kg
60 mg/kg
Sex Male Male
Female Female
Age group Younger SACa Pre-SAC (<5 years)
Older SAC Younger SAC (5–11 years)
Older SAC (12–17 years)
Follow-up time 21 daysa 21 days
28 days
42 days
Abbreviation: SAC, school-age children
aChildren in Kenya were all followed up for 42 days so follow-up was removed
as a covariate
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corresponding to these RRs in Table 5. The estimates in
Fig. 4a indicate that average S. haematobium egg counts
from older SAC (Fig. 5a) after treatment relative to be-
fore treatment are approximately 12 times greater than
those from younger SAC (P-value = 0.016). However, this
seemingly pronounced difference corresponds to an
average ERR of 95.9 % (85.8 %, 98.8 %) compared to
99.7 % (99.4 %, 100 %), respectively (with other covari-
ates set to their baseline values, i.e. males from Côte
d’Ivoire, Table 5).
The estimates in Fig. 4b highlight the increasing trend
in the RRs from 21 days to 28 days to 42 days, corre-
sponding to a decreasing trend in the average ERR (as
also evident by the trend lines in Fig. 3b). Egg counts
made at 42 days after treatment relative to before treat-
ment were 5.77 times greater than those made at 21 days
(P-value = 0.012), corresponding to ERRs of 73.6 and
95.4 % respectively (Table 5). Also noteworthy is that
average egg counts following a 60 mg/kg oral dose of
praziquantel are 66.8 % lower compared with a 40 mg/
Côte d’Ivoire
Older SAC
Côte d’Ivoire
Younger SAC
Kenya
Older SAC
Kenya
Younger SAC
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Fig. 3 Comparison of egg reduction rates among children infected with schistosomes following treatment with praziquantel estimated by
model-free and marginal-model methods. Panels a and b depict, respectively, estimates from individuals infected with Schistosoma haematobium
and S. mansoni. Subplots within each panel are stratified according to the different covariate combinations defined by the marginal model; some
strata are unpopulated and therefore have no data points. Marginal model and model-free estimates are plotted at each follow-up time for ease
of visual comparison. Error bars represent 95 % confidence intervals, calculated using bootstrap methods for model-free sample estimates and
using robust sandwich estimators of the standard error for marginal-model estimates. Circular data points (depicting model-free estimates) that
are coloured grey do not have an associated uncertainty interval since, in the corresponding strata, all egg counts after treatment were zero, and
hence are incompatible with the bootstrap approach. The dashed lines in panel b highlight the decreasing trend in efficacy for increasing follow-
up times as estimated by the marginal model fitted to the S. mansoni data (see Fig. 5 for coefficient estimates)
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kg dose (P-value = 0.064), corresponding to a (not statis-
tically significant) increase in the ERRs from 95.4 to
98.5 %, (with other covariates held at their baseline
values, i.e. male younger SAC in Côte d’Ivoire, Table 5).
Individual egg reduction rates
In Fig. 5 we show individual ERRs across all studies, ad-
justed for covariate fixed effects and estimated by the
classical (frequentist) and Bayesian conditional mixed
models for S. haematobium (Fig. 5a) and S. mansoni
(Fig. 5b). The point estimated ERRs (so-called empirical
best linear unbiased predictors, EBLUPs, Table 1) from
the classical conditional mixed models (denoted by stars
in Fig. 5) indicate that the percentage of individuals with
an ERR of greater than 90 % is 97.7 and 80.7 % for
S. haematobium and S. mansoni respectively. The
Older SAC
Kenya
Female
0.25 1 4 16
Risk ratio
a
Pre−SAC
Older SAC
60 mg/kg
28 days FU
42 days FU
Uganda
Female
0.25 1 4 16
Risk ratio
b
Fig. 4 Coefficient estimates of covariates associated with average egg reduction rates among children infected with schistosomes following treatment
with praziquantel. Panels a and b depict coefficients estimated from the marginal models fitted to the data on, respectively, Schistosoma haematobium
and S. mansoni egg counts measured from children before and after treatment with praziquantel. The coefficient point estimates (black circles)
indicate the multiplicative change (risk ratio, RR) in egg counts after treatment in a particular covariate group compared to the change after treatment
in the reference group. Hence, a RR <1 is associated with an increased efficacy and a RR >1 is associated with a decreased efficacy (compared with the
reference group). Error bars depict 95 % confidence intervals (CIs). A covariate is deemed to exert a statistically significant effect only when its CI does
not cross the vertical grey line at RR = 1. For example, older school-aged children (SAC) infected with S. haematobium are associated with a statistically
significant decrease in efficacy (RR >1) compared to younger SAC
Table 5 The effect of covariates on average egg reduction rates among children infected with schistosomes following treatment
with praziquantel
Covariates Levels ERR (95 % CI)
Schistosoma haematobium dataset
(Baseline) Côte d’Ivoire; male; younger SAC; 40 mg/kg; 21 days follow-up 99.7 % (97.4 %, 100 %)
Country Kenyaa 99.8 % (98.8 %, 100 %)
Sex Female 99.7 % (95.7 %, 100 %)
Age group Older SAC 95.9 % (85.8 %, 98.8 %)
Schistosoma mansoni dataset
(Baseline) Côte d’Ivoire; male; younger SAC; 40 mg/kg; 21 days follow-up 95.4 % (83.1 %, 98.8 %)
Country Uganda 85.3 % (73.5 %, 91.8 %)
Dose 60 mg/kg 98.5 % (90.8 %, 99.8 %)
Sex Female 93.2 % (74.1 %, 98.2 %)
Age group Pre-SAC 95.3 % (80.9 %, 98.8 %)
Older SAC 96.6 % (85.8 %, 99.2 %)
Follow-up time 28 days 84.9 % (76.7 %, 90.1 %)
42 days 73.6 % (53.2 %, 85.1 %)
Abbreviations: CI confidence intervals, SAC school-age children
aChildren in Kenya were followed up for 42 days
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corresponding percentages calculated using the Bayesian
posterior medians (denoted by dots in Fig. 5) are 96.5 and
80.8 %. However, when the uncertainty in the estimated
ERRs is taken into account—by calculating the fraction of
individuals with an ERR > 90 % for each draw from the es-
timated parameter posterior—the median percentages and
associated Bayesian credible intervals (BCIs, given in par-
entheses) are 97.1 % (94.2 %, 98.8 %) and 75.9 % (67.0 %,
81.0 %) for S. haematobium and S. mansoni respectively.
The cumulative distributions (percentiles) of individual
ERRs within strata, estimated from the Bayesian con-
ditional mixed models, are depicted in Figs. 6 and 7
for S. haematobium and S. mansoni respectively. The
corresponding fractions of individual responses greater
than 90 % are given in Table 6. The distributions of ERRs,
like the point estimates shown in Fig. 5, show that prazi-
quantel is highly efficacious in the majority of children
(ERRs > 90 %) but that a substantial minority have ERRs
below the 90 % threshold. In particular, the distributions
estimated from children infected with S. mansoni in
Uganda, or from those followed-up after 42 days, have
longer left tails and greater uncertainty than those esti-
mated from children in Côte d’Ivoire or followed-up after
a shorter duration. In Uganda, the median and 95 % BCI
associated with the proportion of children with an ERR
greater than 90 % is 75.9 % (59.7 %, 86.4 %) compared to
94.4 % (85.3 %, 98.3 %) in Côte d’Ivoire. The correspond-
ing median and 95 % BCI associated with a 42-day follow
up is 59.1 % (39.7 %, 76.4 %) compared to 94.4 % (85.3 %,
98.3 %) with a 21-day follow-up.
Discussion
Modelling methods are currently underused for assessing
anthelminthic drug efficacy. By analysing longitudinal data
on the intensity of schistosome infections before and after
treatment with praziquantel, we show that marginal and
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Fig. 5 Egg reduction rates among children infected with schistosomes following treatment with praziquantel. Panels a and b depict, respectively,
estimates from children infected with Schistosoma haematobium and S. mansoni. Egg reduction rates are calculated from the empirical best linear
unbiased predictors (see Table 1 for definition) estimated from the classical (frequentist) conditional mixed models. Negative estimates of ERRs
(a: n = 1, 0.59 %; b: n = 24, 2.4 %), which correspond to an increase in egg counts after treatment compared to before treatment, are not shown
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conditional mixed models can be used to obtain robust es-
timates of both population- and individual-level efficacies,
while concurrently evaluating the effects of covariates.
While a small number of anthelminthic drug studies
have employed various somewhat unconventional ap-
proaches [33–35], statistical modelling techniques
have not translated into more general use in either
the veterinary or human fields (but see [36]). Beyond
the realm of estimating anthelminthic drug efficacy,
longitudinal and hierarchical modelling techniques are
often used incorrectly across a variety of disciplines
in ecology and evolutionary biology [37], indicating a
general lack of applied understanding about these
powerful analytical tools.
The efficacy of praziquantel within populations and
among individuals
Model-free sample-based methods for estimating anthel-
minthic drug efficacy are hindered by their inherent in-
efficiency in handling covariates (although we note that
the WHO protocol for measuring ERRs recommends
evaluating ERRs at a standardized 21-day follow-up in
SAC using a single test on a single sample before and
after treatment) [16]. Moreover, they can produce biased
estimates when individuals are assessed with different
numbers of repeated measures (e.g. different numbers of
Kato-Katz counts per stool sample, or different numbers
of stool samples, either before or after treatment). This
is because all observations are weighted equally and,
therefore, individuals contributing more observations
disproportionately influence the estimated statistic [38],
i.e. the sample ERR. This probably explains some of the
differences between the model-free and marginal-model
estimates of ERR presented here. Confidence intervals
associated with average ERRs estimated using the mar-
ginal models capture the effect of correlated repeated
measures using robust sandwich estimators of the stand-
ard errors (Table 1). Although the block bootstrap
method used to construct CIs for the model-free ap-
proach accounts for correlation in a more rudimentary
fashion, it is inappropriate in strata when no egg counts
are observed after treatment, generating a statistically in-
valid CI with a width of zero and a 100 % point-
estimated ERR (grey circles in Fig. 3b).
The estimated ERRs of praziquantel against
S. haematobium from both the model-free and marginal
modelling approaches were noticeably higher than those
for S. mansoni (Fig. 4). It is possible that this difference is
driven by a mechanistic superiority of praziquantel against
S. haematobium, for which there is some supportive in
vitro evidence [39]. It is also possible that the difference is
driven by a differential distribution of praziquantel to the
parts of the perivesical venous plexus and the mesenteric/
rectal veins where adult S. haematobium and S. mansoni
flukes reside, respectively [40, 41]. Another possibility is
that the discrepancy in ERRs reflects the presence of
praziquantel-tolerant S. mansoni, which albeit rare, has
been previously observed in the field [12]. By contrast, tol-
erant S. haematobium specimens have not been [8], not-
withstanding the reports of individuals requiring multiple
doses of praziquantel to clear infection [42, 43].
Perhaps most pertinent to the inter-species difference
is that the modelling approaches illustrated here do not
account for the sensitivity of the diagnostic method
(Kato-Katz thick smear for S. mansoni and urine filtra-
tion for S. haematobium diagnosis) and, in particular,
the manner in which sensitivity declines with decreasing
infection intensity, before and after praziquantel admin-
istration [44, 45]. This phenomenon can cause
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Fig. 6 Cumulative distributions of egg reduction rates among
children infected with Schistosoma haematobium following
treatment with praziquantel. Cumulative distributions (black lines)
are constructed from the posterior distributions of the fixed and
random effects components of egg reduction rates estimated from
the Bayesian conditional mixed models. Distributions are depicted
by country, age group and sex in panels a, b and c respectively. In
all panels, covariates not indicated in the legend are set to their
baseline levels, i.e. male younger school-aged children from Côte
d’Ivoire followed up after 21 days, see Table 4. Grey shaded areas
depict 95 % Bayesian credible intervals
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Fig. 7 Cumulative distributions of egg reduction rates among children infected with Schistosoma mansoni following treatment with praziquantel.
Cumulative distributions (black lines) are constructed from the posterior distributions of the fixed and random effects components of egg reduction
rates estimated from the Bayesian conditional mixed models. Distributions are depicted by country, age group, sex, dose and follow-up days in panels
a, b, c, d and e respectively. In all panels, covariates not indicated in the legend are set to their baseline levels, i.e. male younger school-aged children
given 40 mg/kg praziquantel from Côte d’Ivoire followed up after 28 days, see Table 4. Grey shaded areas depict 95 % Bayesian credible intervals
Table 6 The effect of covariates on the percentage of egg reduction rates greater than 90 % among children infected with
schistosomes following treatment with praziquantel
Covariates Levels Percentage ERR > 90 % (95 % BCI)
Schistosoma haematobium dataset
(Baseline) Côte d’Ivoire; male; younger SAC; 40 mg/kg; 21 days follow-up 95.9 % (89.3 %, 99.1 %)
Country Kenyaa 98.3 % (94.3 %, 99.7 %)
Sex Female 97.3 % (92.2 %, 99.4 %)
Age group Older SAC 92.3 % (82.6 %, 97.6 %)
Schistosoma mansoni dataset
(Baseline) Côte d’Ivoire; male; younger SAC; 40 mg/kg; 21 days follow-up 94.4 % (85.3 %, 98.3 %)
Country Uganda 75.9 % (59.7 %, 86.4 %)
Dose 60 mg/kg 92.3 % (77.8 %, 98.1 %)
Sex Female 92.6 % (81.8 %, 97.6 %)
Age group Pre-SAC 90.9 % (78.1 %, 97.2 %)
Older SAC 95.5 % (85.8 %, 99.0 %)
Follow-up time 28 days 89.5 % (80.4 %, 95.0 %)
42 days 59.1 % (39.7 %, 76.4 %)
aChildren in Kenya were followed up for 42 days
Abbreviations: BCI Bayesian credible interval, SAC school-age children
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overestimation of drug efficacy [23, 46] with differential
bias between species if the severity of this effect is differ-
ent between the urine filtration technique and the Kato-
Katz method. Moreover, it is assumed that the specificity
of the diagnostic methods are 100 %, with no incorrect
identification of schistosome eggs in truly negative sam-
ples. In particular, as the intensity of infection declines
after treatment, the number of true negative samples in-
creases, increasing the probability of false positives, even
with very good specificity. The next generation of mod-
elling frameworks must account for the sensitivity and
specificity of the diagnostic method and capture how it
varies with the underlying intensity of infection.
While marginal models are powerful tools for asses-
sing stratum-level average efficacy (average ERRs), con-
ditional mixed models offer additional insight at the
level of the individual. The individual estimates of ERRs
reveal numerous so-called sub-optimally responding
individuals, with an efficacy lower than the WHO’s em-
pirical 90 % threshold for group average. A similar result
is presented in the recent sample-based analysis of the
full 13-study database (see Additional file 1: Supplementary
Tables, Table S1) [14]. A substantive 3.7 % of children
infected with S. mansoni had ERRs of less than 50 % (Fig. 6)
and more than twice as many children infected with S.
mansoni had an ERR below 90 % compared with those
infected with S. haematobium (10.4 % versus 4.0 %).
Suboptimal or atypical responses to praziquantel have
been previously described in terms of the number of
doses necessary to clear the parasite, with any result
above one dose considered suboptimal [42, 43, 47–49].
Compared to this measure of sub-optimality, conditional
mixed models offer a more nuanced insight into the distri-
bution of drug responses among individuals.
When does the efficacy of praziquantel appear greatest?
The observed efficacy of an anthelminthic crucially de-
pends on when after treatment measurements of infec-
tion intensity (or presence/absence of transmission
stages) are made. This is because efficacy is a snapshot
of the competing dynamics of parasite clearance,
followed by reinfection [50] or repopulation initiated by
surviving parasites, perhaps subjected to temporarily re-
duced or inhibited fertility or, in the case of praziquantel,
maturation of juvenile parasites [45].
Our results indicate that, among children infected with
S. mansoni, average ERRs decreased from follow-up
times of 21 days to 28 days, and from 28 days to 42 days.
This mirrors the findings of a meta-analysis of 11 studies
of the efficacy of praziquantel against S. mansoni in
Africa where a similar relationship between longer
follow-ups and lower CRs was interpreted as being prob-
ably due to reinfection [48]. Repopulation by surviving
juvenile parasites is another likely cause. Schistosomes
exhibit a biphasic susceptibility to praziquantel through-
out their lifecycle; early-stage migrating larvae are sus-
ceptible to praziquantel, but after about one month of
growth, susceptibility drops precipitously, and is only
regained after another two months [51]. Therefore, by
42 days after treatment, many of the juvenile schisto-
somes that survived treatment may have matured or
repopulated the organs of preferred location as fertile
egg-producing adult schistosomes. Moreover, recent
studies using circulating cathodic antigen (CCA) tests
indicate that 50–100 % of praziquantel-treated children
retain their antigenemia/antigenuria when retested 1–7
weeks after treatment [52, 53]. Hence, the effective
praziquantel efficacy is probably much lower than previ-
ously thought and surviving parasites are also likely con-
tributors to the recovery in egg counts after treatment.
We did not have access to data collected at shorter
follow-up times, to perhaps model when ERRs are at a
maximum, although analyses presented elsewhere [23]
have suggested that this occurs 2–3 weeks after treat-
ment, which is the timeframe currently recommended
by WHO [13].
Why does age affect the efficacy of praziquantel?
The decreasing (weak and not statistically significant)
trend in estimated ERRs with increasing age (pre-SAC to
younger SAC to older SAC, see Figs. 5b and 7c) of chil-
dren infected with S. mansoni is in accordance with sev-
eral existing hypotheses. Older children are likely to
have stronger acquired immunity to schistosomes than
younger children [54], as flukes killed or damaged from
exposure to praziquantel release previously ‘unseen’ anti-
gens [55–58] eliciting protective immune responses
thought to enhance (but not always [59]) the efficacy of
subsequent treatments [60, 61]. Consequently, one
might expect older children to be more amenable to
treatment and exhibit higher ERRs than their younger
counterparts. However, and crucially, the data analysed
here were collected from communities unexposed or
minimally exposed to praziquantel MDA (see selection
criteria in Fig. 1). Hence, older children in these com-
munities might be more difficult to treat and respond
less well to praziquantel having been left to grow older
with untreated schistosome infections. This might ex-
plain the estimates from the marginal model indicat-
ing that the average ERR from older SAC infected
with S. haematobium is markedly lower than that
from younger SAC. Alternatively, this result may re-
flect a general limitation of the analysis. For example,
most of the studies under consideration encompassed
multiple villages or study areas within a single coun-
try, but village-level identifiers were not available, and
small-scale variation in praziquantel responses among
villages can be quite large [62].
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How does infection intensity affect the efficacy of
praziquantel?
Numerous studies have demonstrated a negative associ-
ation between the infection intensity before treatment
and estimated CRs following treatment with praziquantel;
the higher the intensity, the lower the CR [20, 48, 63]. This
is because, if adult schistosomes die with a fixed prob-
ability when exposed to praziquantel, cure will be less
likely in heavily infected individuals than in lightly in-
fected individuals. Indeed, the WHO no longer recom-
mends using CRs for the monitoring and evaluation
(M&E) of anthelmintic efficacy [13] because it is impos-
sible to observe incremental reductions in parasite bur-
den using a binary measure of cure and, therefore, CRs
fail to capture the impact of multiple doses of anthel-
minthic drugs over the course of PCT programmes
[64]. In this work, we constructed the conditional
mixed models to estimate the association between an
individual’s egg count before treatment (the random
intercept term) and their ERR (governed by the random
‘gradient’ term, see Additional file 1: Supplementary
Methods, S3 Conditional mixed models), but we found
no statistically significant relationship. Intuitively, again
invoking the assumption of a constant probability of
death by praziquantel, the percentage reduction in in-
tensity will be constant, explaining why there is no as-
sociation between egg counts before treatment and the
estimated ERR.
Modelling for M&E of MDA interventions
Modelling has an important role in the M&E of anthel-
mintic drug efficacy in the context of human helminth
PC programmes. Marginal models offer a robust method
of estimating (sub-) population-level drug efficacy, which
would allow disease control managers to identify
whether or not target ERRs are being met. Such targets
could be defined using data from populations predomin-
antly naïve to MDA, in different demographic groups,
which may respond in a systematically differential man-
ner to drug treatment. Individual-level ERRs estimated
using conditional mixed models offer an additional
depth of insight, permitting characterisation of the dis-
tribution of drug responses among individuals. This is
important for the rapid identification of changing re-
sponses to anthelminthic drugs that may be indicative of
declining drug efficacy, potentially caused by emerging
drug-resistant parasites [6, 10–12, 49]. By comparing the
observed distribution of drug responses to a reference
distribution of expected responses estimated before
MDA—ideally from the same community, but otherwise
using data from demographically and geographically
matched or partially matched populations—it would be
possible to identify whether or not individuals are
responding aberrantly to the drug. That is, one could
quantify how atypical an observed response is compared
to the usual or expected distribution of responses. Indi-
viduals responding suspiciously could be investigated,
perhaps using in vitro drug sensitivity tests on the infect-
ing parasites. Moreover, over multiple rounds of MDA,
one could identify shifts in the distribution of responses
from the original reference distribution; shifts towards
decreased efficacy triggering further programmatic and
parasitological investigation.
Conclusions
Marginal and conditional mixed models are robust ap-
proaches for calculating population- and individual-level
estimates of anthelminthic drug efficacy. We illustrate
these techniques by analysing data collated from nine
previous studies on schistome egg counts from children
before and after administration of praziquantel. We
show that model-based analyses: (a) offer more stable
and robust estimates of average ERRs compared to trad-
itional sample-based methods, especially when sample
sizes are small; (b) can be used to evaluate how and to
what degree drug responses vary among population
strata, in terms of an average response, and among indi-
viduals within a stratum, in terms of the distribution of
individual responses. We show that Bayesian methods
are particularly useful in quantifying uncertainties, and
permit creation of prototype ‘reference’ distributions
describing the range of drug responses expected in com-
munities predominantly naïve to MDA. These distribu-
tions have potentially important applications to the
M&E of anthelmintic efficacy in helminthiasis PCT pro-
grammes, particularly for identifying individual atypical
responses and distributional shifts, potentially indicative
of emerging drug resistance. Therfore, the approaches il-
lustrated in this paper have an important role in support-
ing the control and elimination of human helminthiases.
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